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Abstract 
Background:  Atrial fibrillation (AF) and heart failure frequently coexist, commonly 
resulting in serious adverse events.  With both conditions increasing in prevalence and 
justified concerns about treatment efficacy, it is vital to understand how the type of heart 
failure impacts on prognosis.  
Methods:  We performed a systematic review of studies examining cardiovascular outcomes 
in AF patients with heart failure and reduced ejection fraction (AF-HFrEF) compared to those 
with preserved ejection fraction (AF-HFpEF).  The primary outcome was all-cause mortality, 
meta-analyzed using a random-effects model.  Prospective registration: PROSPERO-
CRD42014007305. 
Results:  Thirteen studies were included in the systematic review (n=54,587) with 10 suitable 
for meta-analysis, including retrospective/prospective cohorts and sub-group analyses of 
randomized trials.  AF-HFrEF was present in 49% and these patients were younger, more 
often male and with higher NYHA class than AF-HFpEF.  Oral anticoagulation use was 55% 
versus 50% respectively (p<0.001).  All-cause mortality was significantly higher in AF-
HFrEF; risk ratio (RR) 1.24, 95% CI 1.12-1.36, p<0.001 (n=45,100), with absolute death 
rates of 24% compared to 18% in AF-HFpEF over 2 years.  There were no significant 
differences in incident stroke (RR 0.85, 95% CI 0.70-1.03, p=0.094; n=33,773) or heart 
failure hospitalization (RR 1.21, 95% CI 0.96-1.53, p=0.115; n=31,583).  The risk of bias 
was generally low, but heterogeneity was substantial. 
Conclusions:  All-cause mortality is significantly higher in AF patients with HFrEF 
compared to HFpEF, although stroke risk and heart failure hospitalization are similar.  
Further studies are needed to address the prevention of adverse outcomes in all AF patients 
with heart failure, regardless of ejection fraction.
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Abbreviations 
AF   Atrial fibrillation 
CI   Confidence interval 
HFpEF  Heart failure with preserved ejection fraction 
HFrEF   Heart failure with reduced ejection fraction 
HR   Hazard ratio 
MI    Myocardial infarction 
NYHA   New York Heart Association  
RR   Risk ratio 
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Introduction 
Atrial fibrillation (AF) is the most common cardiac arrhythmia and is associated with 
increased rates of mortality and serious morbidity, including stroke, worsening of heart 
failure, sudden death, and reduced quality of life.1  Both the incidence and prevalence of AF 
are expected to double in the next 20 years.2  Patients with AF are twice as likely to be 
hospitalized as matched controls, with direct medical costs estimated to be 73% higher than 
non-AF patients.3  Further, AF is an independent predictor of all-cause mortality, with a two-
fold adjusted increase in death.4, 5  While most strokes in AF can be prevented by oral 
anticoagulation, cardiovascular deaths in AF patients are mostly related to progressive heart 
failure or sudden death.6-8  In the context of those diagnosed with a heart failure syndrome, 
the presence of AF leads to higher rates of death and hospitalization, regardless of other risk 
variables or which condition comes first.9, 10  Depending on the severity of HF, up to 50% of 
symptomatic patients will be diagnosed with AF, representing a large and growing unmet 
clinical need for healthcare improvement.11 
 
Current risk stratification schemes for AF focus on preventing strokes and systemic embolism 
by identifying patients at risk that either require or do not require oral anticoagulation.1, 12  
Both the CHADS2 and CHA2DS2-VASc schemes incorporate a history of heart failure as a 
risk marker, although based on differing definitions and detection methods.  There is 
conflicting evidence on whether heart failure with reduced ejection fraction (HFrEF) is the 
major driver for adverse clinical events or if heart failure with preserved ejection fraction 
(HFpEF) is equally important.13-15  With regards to prediction of mortality, analysis of the 
Randomized Evaluation of Long-Term Anticoagulant Therapy (RE-LY) trial identified heart 
failure as an independent predictor of all-cause mortality in AF (adjusted for ejection 
fraction) and the strongest predictor of cardiac death.6  We have recently demonstrated that in 
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contrast to patients in sinus rhythm, those with HFrEF and concomitant AF do not benefit 
from beta-blocker therapy in terms of all-cause mortality, cardiovascular mortality or 
hospitalization.8  This highlights the importance of analyzing outcomes specifically in AF, 
rather than extrapolating from patients with sinus rhythm.  With the prevalence of HFpEF 
now equal to that of HFrEF16, understanding the relative effects on major adverse events in 
patients with AF is of major clinical importance and requires further clarification.  Our 
objectives were to systematically assess the available literature on AF patients with heart 
failure to determine if clinical outcomes in AF-HFpEF were similar to those in AF-HFrEF.    
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Methods 
Eligibility criteria & search strategy 
All studies examining comparative outcomes in AF-HFrEF and AF-HFpEF were 
evaluated, regardless of study design.  All cardiovascular outcomes and all populations were 
considered, including sub-sets of AF patients from larger trials.  We excluded studies that did 
not provide comparative outcomes or were not published as full-text articles.  The definitions 
used by each individual study were accepted, including those of AF, heart failure and whether 
ejection fraction was preserved or not.  A systematic review of MEDLINE (1950 to 
November 2013 and subsequently extended to August 2014), EMBASE (1980 to December 
2013) and the Cochrane Library (until December 2013 and subsequently extended to August 
2014) were performed without language restriction (see study selection diagram in Figure 1).  
We also manually searched reference lists of relevant studies, investigated registers of 
ongoing trials and included studies after discussion with content experts.  The review was 
conducted according to the Preferred Reporting Items for Systematic reviews and Meta-
Analyses (PRISMA) guidelines.17  The project was prospectively registered with the 
PROSPERO database of systematic reviews (CRD42014007305).18 
 
Data collection and quality assessment 
Two investigators (RC and DK) independently extracted and tabulated data in a 
standardized data-extraction form.  Discrepancies and missing data were resolved by group 
discussion, reference to the original publication and additional independent adjudication.  
Unadjusted data were extracted for meta-analysis and adjusted data for systematic review.  
Additional unpublished data were provided from the lead authors of two studies.8, 19  The 
study by Kotecha et al (2014) includes pooled individual patient data from 10 randomized 
7 
controlled trials of beta-blockers in patients with heart failure.20  In another study, outcome 
rates were extrapolated from the 88.9% of patients with available follow-up.21  Study quality 
was assessed using the Cochrane Collaboration’s Risk of Bias tool and the Risk of Bias 
Assessment Tool for Non-randomized Studies (RoBANS), which address key criteria such as 
selection bias, exposure measurement, blinding, the completeness of outcome data and 
selectivity of reporting.22, 23  
 
Primary and Secondary Outcomes 
 The predefined primary outcome was all-cause mortality.  Secondary outcomes of 
interest were incident stroke, systemic embolism, myocardial infarction (MI), heart failure 
hospitalization and major bleeding.  Meta-analysis was suitable for three outcomes; all-cause 
mortality, incident stroke and heart failure hospitalization. 
 
Statistical analysis 
 Demographics were averaged using a weighted mean (and standard deviation) with t-
tests used for between-group comparisons.  Meta-analysis was pre-specified to use a random-
effects model as the true effect size was likely to vary in the individual studies owing to the 
variety in populations assessed and different study designs.  Pooled binary event data for AF-
HFrEF and AF-HFpEF were compared using a risk ratio (RR) with associated 95% 
confidence intervals (CI) using the method of DerSimonian and Laird.24  Sensitivity analyses 
for the primary outcome were performed according to a pre-defined mean anticoagulation 
rate of 70% and by study design (post-hoc examination of randomized subjects compared to 
cohort studies).  The latter analysis utilized a fixed-effects model with the method of Mantel 
and Haenszel25.  Three additional post-hoc analyses were performed for the primary outcome: 
(1) according to ejection fraction cut-off for HFpEF (<50% or ≥50%); (2) whether the 
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population was derived predominantly from heart failure or AF patients; and (3) a sensitivity 
analysis excluding the largest study.  Heterogeneity was assessed using the chi-squared test 
and I2 statistic, with the estimate of heterogeneity taken from the inverse-variance fixed-
effects model.  Publication bias was assessed using a funnel plot, Begg’s test and Egger’s 
test.  A two-tailed p-value of 0.05 was considered statistically significant.  Analyses were 
performed on Stata Version 11.2 (StataCorp LP, Texas).  
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Results 
We identified 13 studies (see Figure 1) which included 54,587 patients with AF and 
heart failure from a total population studied of 179,585 (30%).  The risk of bias was generally 
low, except for incomplete outcomes due to the selection bias of including participants with 
available echocardiography data (see Supplementary Table A).  Study descriptors are 
summarized in Table 1.  From the 10 studies included in the meta-analysis (n=45,100), 5 
were retrospective or prospective cohorts19, 21, 26-28 and 5 were sub-group analyses of 
randomized trials.29-32  One study examined outcomes at 30 days after heart failure 
admission26, however the length of follow-up in the remainder was 1.9 years (weighted-
average) with a range of 1.5-3.4 years.  AF-HFrEF was present in 48.5% of patients and AF-
HFpEF in 51.5%.  Three cohort studies did not present unadjusted data and are discussed 
separately from the meta-analysis.33-35   
Pooled demographics are presented in Table 2.  On average AF-HFrEF patients were 
4 years younger and had a higher proportion of males and prior MI than those with AF-
HFpEF.  AF-HFrEF patients typically had higher NYHA class (i.e. more symptomatic than 
AF-HFpEF).  Mean ejection fraction ranged from 26-35% in AF-HFrEF and 51-63% in AF-
HFpEF, with a variety of cut-off values for HFpEF, including 40%, 45%, 50% and 55%.  
Detailed characteristics by study, including a comparison of drug therapy, are presented in 
Supplementary Table B.  Of particular note were the low rates of anticoagulation use 
(particularly in the cohort studies), despite indications for oral anticoagulation (mean 
CHADS2 scores ranging from 2.0 to 3.3).  Oral anticoagulant use was higher in those patients 
with AF-HFrEF compared to AF-HFpEF (p<0.001). 
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All-cause mortality 
Ten studies were suitable for unadjusted meta-analysis of the primary outcome, totaling 
45,100 patients.8, 19, 21, 26-32  All-cause mortality was significantly higher in AF-HFrEF, with a 
pooled risk ratio of 1.24 compared to AF-HFpEF (95% CI 1.12-1.36, p<0.001; see Figure 2).  
In AF-HFrEF, all-cause mortality in 9 individual studies with long-term follow-up ranged 
from 13 to 55% and overall 24% of patients died (2088/8785).8, 19, 21, 27-32  In AF-HFpEF, all-
cause mortality in the 9 long-term studies ranged from 8 to 50% and overall 18% of patients 
died (1017/5758).   
Sub-group analysis by study type confirmed higher mortality in AF-HFrEF compared to AF-
HFpEF in both the post-hoc assessments of randomized trials as well as cohort studies (see 
Supplementary Figure A), with the difference in mortality greatest in the post-hoc 
randomized trials (interaction p=0.02).  The relative increase in mortality for the AF-HFrEF 
group was unaffected by the average rate of anticoagulation (interaction p=0.83; see 
Supplementary Figure B) or by ejection fraction cut-off (interaction p=0.17; see 
Supplementary Figure C).  In an exploratory meta-analysis, we also confirmed higher 
mortality in AF-HFrEF compared to AF-HFpEF regardless of whether the study population 
was predominantly heart failure (RR 1.24, 95% CI 1.04-1.49, p<0.001) or derived from 
patients with AF (RR 1.24, 95% CI 1.11-1.38, p=0.016), with an interaction p-value of 0.96.  
Results were unaffected by removal of the largest included study26 (RR 1.23, 95% CI 1.09-
1.39; p=0.001). There was no evidence of significant publication bias for the primary 
outcome (see Figure 3), although this cannot be excluded in light of the small number of 
trials and degree of heterogeneity. 
Three studies provided adjusted HR for all-cause mortality comparing AF-HFrEF with AF-
HFpEF, which were all consistent with the unadjusted meta-analysis results.8, 28, 29  It was not 
appropriate to pool these results due to substantial differences in the adjustment variables 
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within each analysis (see Supplementary Table C).  Of the studies not included in the meta-
analysis, results from Pedersen et al were consistent with the overall results (long-term 
mortality greater in AF patients with an ejection fraction <35%).35  McManus et al reported 
on a community cohort of heart failure patients and identified similar adjusted hazard ratios 
(HR) for pre-existing AF compared to sinus rhythm in HFrEF (1.15, 95% 1.05-1.26) and 
HFpEF (1.11, 95% CI 1.03-1.20).34   
 
Incident stroke 
Seven studies including 33,773 subjects were suitable for meta-analysis of incident stroke 
(see Figure 4A).8, 19, 26, 28, 29, 31, 32  Of note, the follow-up period for stroke was short, with one 
study including in-hospital strokes only (mean duration of hospital admission 6.3 [range of 0-
56] days)28 and one study assessing 30-day readmission for ischemic stroke.26  Two studies 
included fatal and non-fatal strokes.8, 32  The rate of incident stroke was similar at 1.6% in 
AF-HFrEF (269/16967) and 1.3% in AF-HFpEF (213/16806).  Meta-analysis revealed no 
significant difference between groups (RR 0.85, 95% CI 0.70-1.03, p=0.094). 
One additional study not included in the meta-analysis discussed stroke as an outcome.  
McManus et al reported that pre-existing AF was associated with ischemic stroke only in 
those with HFpEF (adjusted HR compared to sinus rhythm 1.91, 95% CI 1.56-2.33; versus 
1.07, 95% CI 0.82-1.39 in HFrEF).34  
 
Heart failure hospitalization 
Five studies including 31,583 patients were suitable for meta-analysis of heart failure 
hospitalization.8, 26, 30-32  There was a numerical excess in those with AF-HFrEF, with 13.7% 
having one or more hospitalizations (2159/15779), compared to 7.9% in patients with AF-
HFpEF (1256/15804).  However this was not statistically significant on meta-analysis with 
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RR 1.21, 95% CI 0.96-1.53, p=0.115 (see Figure 4B). 
Heart failure hospitalization was reported in two additional studies not included in the meta-
analysis, both of which noted a non-significant but numerical excess in AF-HFrEF.  Badheka 
et al reported an adjusted HR comparing AF-HFrEF with AF-HFpEF of 1.12 (95% CI 0.93-
1.33, p=0.24)29 and McManus et al reported an adjusted HR compared to sinus rhythm of 
1.26 (95% CI 1.17-1.37) for AF-HFrEF and 1.16 (95% CI 1.05-1.27) for AF-HFpEF.34   
 
Other outcomes 
There were limited data available on other clinical outcomes.  Parkash et al assessed in-
hospital MI only (over 6.3 days) and found a lower rate in patients with AF-HFpEF (2.3% 
versus 7.3% with AF-HFrEF; p=0.012).28  In Kotecha et al, there were very few incident MI 
events on longer term follow-up, numbering 47/3000 patients (1.6%) overall and no 
significant difference between AF-HFrEF and AF-HFpEF (p=0.16).8  Rates of 
thromboembolism were reported in two studies, with no difference between groups: AF-
HFrEF 19/691 (2.7%) for Banerjee et al19 and 5/2736 (0.2%) for McMurray et al31 compared 
to AF-HFpEF 17/585 (2.9%) and 8/3207 (0.2%) respectively.  Badheka et al also 
documented no difference in progression of NYHA class between groups.29  Three studies 
(n=7,941) reported on bleeding outcomes for AF-HFrEF versus AF-HFpEF, with no 
differences identified in the rate of bleeding.19, 29, 31  
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Discussion 
In this systematic review and meta-analysis of over 54,000 patients, our principal 
finding was a significantly higher risk of death in AF patients with HFrEF compared to those 
with HFpEF.  There was a crude mortality rate of 24% versus 18% respectively, over an 
average follow-up period of 2 years.  Importantly, we identified no significant difference in 
incident stroke or heart failure hospitalization between the two groups.  There was no 
consistent evidence of any difference in other cardiovascular or bleeding outcomes, however 
the use of anticoagulation was substantially below recommended levels.   
 
Atrial fibrillation and heart failure commonly coexist.11  Regardless of which 
condition arises first, patients suffer a substantial increase in cardiovascular and non-
cardiovascular morbidity, as well as increased mortality, both in those with pre-existing and 
new-onset AF.36, 37  Recent years have seen a focus on preventing strokes and 
thromboembolism in AF, with numerous large trials of novel oral anticoagulants.  However, 
the principal causes of cardiovascular mortality in AF remain progressive heart failure and 
sudden death.6  Heart failure can occur as a consequence of AF, secondary to the rapid pulse 
and morphological changes to atrial and ventricular structure and function (tachycardia-
induced cardiomyopathy).  Conversely, structural changes in chronic heart failure patients, 
with the addition of neurohormonal activation, make AF much more prevalent and can 
worsen ventricular function (tachycardia-accelerated cardiomyopathy).  Furthermore, AF and 
heart failure may in some patients have a common cause (for example a genetic or acquired 
predisposition to cardiac dysfunction).  As such, the two conditions are inter-connected and 
frequently seen in clinical practice.3, 38   
Studies in heart failure have typically enrolled patients with left-ventricular systolic 
dysfunction, whereas outcomes in HFpEF have been less well documented.  The latter, in 
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which impairment of diastolic relaxation leads to signs and symptoms of heart failure, is 
equal in prevalence or more common than HFrEF16 and is associated with similar risk factors 
to those predicting mortality in AF patients.39, 40  Hence defining clinical differences between 
the two types of heart failure is paramount, both for risk-stratification and patient 
management as well as healthcare policy generation.  Comparative data on cardiovascular 
outcomes in patients with AF have been conflicting, resulting in a lack of focus on mortality 
as a preventable outcome in both AF-HFrEF and AF-HFpEF. 
   
Our results showing excess mortality in AF-HFrEF are consistent with data for all 
heart failure patients, regardless of rhythm status.  The Meta-analysis Global Group in 
Chronic Heart Failure (MAGGIC), performed an individual-patient meta-analysis of 41,972 
subjects, with 79% in sinus rhythm.41  Those with HFpEF were at a lower risk of death than 
HFrEF with a crude HR of 0.71, 95% CI 0.67-0.74 (the corresponding RR in our analysis was 
0.81, 95% CI 0.73-0.89).  We deliberately assessed data in unadjusted form, as the presence 
of interacting confounders in sub-group assessment cannot be controlled within a tabular 
meta-analysis.  However there is little evidence of any modifying effect on risk, either in the 
MAGGIC analysis41 or within the three studies that provided adjusted HR for direct 
comparison of AF-HFrEF with AF-HFpEF.  There was a small but significant difference in 
age between the groups, however AF-HFpEF patients were older and adjustment would 
likely have exaggerated the divergence on mortality demonstrated.  We did note a significant 
interaction according to study design, with data obtained from randomized studies showing 
higher death rates even with better medical therapy.  Whilst this could represent a chance-
effect, it could also be explained by selection biases within the randomized cohorts, 
particularly as patients were not randomized on the basis of their ejection fraction.  No 
interactions were identified according to population, anticoagulation rate or ejection fraction 
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cut-off, suggesting that our finding of increased mortality in AF-HFrEF is consistent despite 
differences in study settings and methodology. 
 
Medical therapy was surprisingly sub-optimal in the community cohorts with 
relatively poor uptake of ACE inhibitors and beta-blockers in AF-HFrEF patients compared 
to the randomized trials.  This may reflect the view of clinicians on the benefit of these drugs 
in heart failure patients with AF, compared to the published data which predominantly relates 
to those in sinus rhythm.  We have recently demonstrated that beta-blockers in HFrEF 
patients with AF do not reduce all-cause mortality, with an adjusted HR of 0·97 (95% CI 
0·83-1·14) versus placebo, compared to 0·73 (95% CI 0·67-0·80) in those with sinus rhythm 
(interaction p=0.002).8  We also identified no significant reduction in cardiovascular and 
heart failure related hospitalization in AF-HFrEF patients given beta-blockers, highlighting 
the importance of obtaining AF-specific data, rather than extrapolation from other 
populations.   
Regardless of study design, the use of anticoagulation was noticeably discordant with 
current guidelines.42, 43  Only 55% in the AF-HFrEF group and 50% with AF-HFpEF were on 
oral anticoagulation despite having risk factors for stroke that should lead to initiation of 
therapy.  Strokes in patients with AF are associated with larger neurological deficits, longer 
hospital stays, lower discharge rates to home and higher mortality.44  We did not identify any 
significant difference in incident stroke between AF-HFrEF and AF-HFpEF, consistent with 
recently published data.45  As such, both groups of patients should receive adequate 
anticoagulation, with vitamin K antagonists (VKA) or non-VKA oral anticoagulants, in order 
to attain low rates of residual adverse events.46  With regards to risk assessment using the 
CHA2DS2-VASc score1, our data confirm that the presence of heart failure is important, 
regardless of ejection fraction.47 
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Limitations 
This review is based on tabular reported results of independent studies prepared 
according to explicit, reproducible methodology22 of published and unpublished data.  The 
main limiting factor in these analyses were the component studies, which by their nature were 
observational cohorts, either post-hoc examinations of randomized trials or cohort studies.  
Patients with AF-HFrEF/AF-HFpEF constituted 30% of the total population studied and 
therefore selection biases should be considered.  Owing to the expected differences in study 
design and populations, we pre-specified a random-effects model, with additional fixed-effect 
sensitivity analyses of the primary outcome and relevant sub-groups.  Substantial 
heterogeneity was noted for all-cause mortality, although this was rendered non-significant 
by stratification according to study design.  There were insufficient data to perform meta-
regression on baseline variables such as age and gender.  Publication bias was not identified, 
although funnel plot symmetry and associated statistical measurements can be misleading, 
particularly in cases where heterogeneity is high.48  The methodological quality of the 
included studies was variable and the incident stroke rate was low, although this likely 
reflects the short follow-up periods for this particular outcome.  Very few studies recorded 
the type of AF (paroxysmal/persistent/permanent) and there was inconsistency in the ejection 
fraction cut-off for HFpEF.  Future studies would be improved by using a standardized 
criterion (for example >50% as suggested by heart failure guidelines16, 49) and ensuring that 
patients with AF are adequately anticoagulated.   
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Conclusion 
Patients with atrial fibrillation and heart failure have substantial morbidity regardless of left-
ventricular ejection fraction.  Systematic review of over 54,000 patients demonstrates higher 
rates of all-cause mortality in those with reduced ejection fraction but similar stroke risk and 
heart failure hospitalization compared to patients with preserved left-ventricular function.  
Further attention is warranted to refocus on mortality as a preventable outcome, to 
standardize the diagnosis of preserved ejection fraction and to improve the rate of 
anticoagulation in all AF patients with heart failure. 
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Table 1:  Description of studies 
Study Design Sample size Follow-up period HFpEF definition 
Badheka, 2011 29 Post-hoc analysis of AF patients randomized to rate versus rhythm-control (AFFIRM trial) 
722 with HF and documented LVEF, from a 
total population of 4060 Mean 3.4 years ≥ 50% 
Banerjee, 2012 19 Retrospective cohort study of patients diagnosed with AF at a single French cardiology unit 
1276 with non-valvular AF and LVEF 
available, from a total population of 7156 Mean 1.3 years ≥ 50% 
Eapen, 2013* 26 Retrospective cohort study of patients admitted with decompensated HF (ADHERE-Core Medicare registry) 
30557 with AF and LVEF recorded, from a total 
population of 80416 30 days ≥ 40% 
Fung, 2007 33 Prospective cohort study of patients admitted with HF 72 with AF, from a total population of 238 Median 0.88 years ≥ 50% 
Kotecha, 2014 8 Post-hoc analysis of HF patients randomized to beta-blockers or placebo pooled from 10 trials (BB-meta-HF) 
3050 with AF and LVEF recorded, from a 
population of 18254 Mean 1.5 years ≥ 45% 
Linssen, 2011 30 Post-hoc analysis of HF patients randomized to different levels of counselling and support 
336 with AF and interpretable echocardiograms, 
from a total population of 1023 1.5 years ≥ 40% 
McManus, 2013 34 Retrospective cohort study of heart failure patients from 4 centers in US 
9081 with pre-existing AF, from a total 
population of 23,644 Median 1.8 years ≥ 50% 
McMurray, 2013 31 Post-hoc analysis of AF patients randomized to a novel oral anticoagulant or warfarin  (ARISTOTLE trial) 
5943 with AF and either HFrEF or HFpEF, 
from a total population of 18201 Median 1.5 years > 40% 
Olsson, 2006 32 Post-hoc analysis of HF patients randomized in 3 studies to an angiotensin receptor blocker or placebo (CHARM trials) 1148 with AF, from a total population of 7601 Median 3.1 years > 40% 
Pai, 2007 27 Retrospective cohort study of patients undergoing echocardiography at a single US center 1168 with AF, from a total population of  8,931 Mean 2.6 years ≥ 55% 
Parkash, 2005 28 Retrospective cohort study of patients attending a single US emergency department with HF and AF 
478 with an echocardiogram within 1 month, 
from a total population of 1749 Mean 3.3 years > 50% 
Pedersen, 2005 35 Prospective cohort study of patients admitted to 27 Danish centers with an acute myocardial infarction 
332 with AF/atrial flutter, HF history and LVEF 
from a total population of 6676 5 years > 50% 
Shamagian, 2006 21 Retrospective cohort study of patients admitted for HF at a single Spanish cardiology unit 
424 with AF and measured LVEF, from a total 
population of 1636 Mean 3.1 years ≥ 50% 
AF, atrial fibrillation; HF, heart failure; LVEF, left-ventricular ejection fraction; AFFIRM, Atrial Fibrillation Follow-Up Investigation of Rhythm Management; ADHERE, Acute 
Decompensated Heart Failure National Registry; BB-meta-HF, Beta-blockers in Heart Failure Collaborative Group; ARISTOTLE, Apixaban for Reduction in Stroke and Other 
Thromboembolic Events in Atrial Fibrillation; CHARM, Candesartan in Heart Failure-Assessment of Reduction in Mortality and Morbidity.  * E-published 2013; in-print 2014. 
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Table 2:  Pooled weighted characteristics 
 
Characteristic AF-HFrEF AF-HFpEF 
Age, mean (SD) 74.6 years 78.5 years 
Male, % 67.7% 41.1% 
Prior myocardial infarction, % 38.3% 22.5% 
Diabetes, % 32.0% 32.7% 
LVEF, mean % 30.7% 56.4% 
Oral anticoagulant use, % 54.8% 49.9% 
Pooled results for 10 studies (where data available), weighted according to sample size. 
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Supplementary Table A:  Risk of bias assessment 
 
Study Selection of participants 
Confounding 
variables 
Measurement 
of exposure 
Blinding of 
outcome  
Incomplete 
outcome data 
Selective 
reporting 
Badheka, 2011 Low risk Low risk Low risk Unclear High risk Low risk 
Banerjee, 2012 Low risk Low risk Low risk Unclear High risk Low risk 
Eapen, 2013 Low risk Low risk Low risk Low risk High risk Low risk 
Fung, 2007 Low risk Unclear Low risk Unclear Unclear Low risk 
Kotecha, 2014 Low risk Low risk Low risk Low risk Low risk Low risk 
Linssen, 2011 Low risk Low risk Low risk Low risk High risk Low risk 
McManus, 2013 Low risk Low risk Low risk Unclear High risk Low risk 
McMurray, 2013 Low risk Low risk Low risk Low risk High risk Low risk 
Olsson, 2006 Low risk Low risk Low risk Low risk Low risk Low risk 
Pai, 2007 Low risk Unclear Low risk Unclear Unclear Unclear 
Parkash, 2005 Low risk Low risk Low risk Unclear High risk Low risk 
Pedersen, 2004 Low risk Unclear Low risk Low risk High risk Low risk 
Shamagian, 2005 Low risk Low risk Low risk Unclear High risk Unclear 
Risk of bias reported for each domain using the Risk of Bias Assessment Tool for Non-randomized Studies (RoBANS).23  High risk in the incomplete outcome data category is attributed 
to the inherent selection biases of assessing patients with an available measurement of ejection fraction. 
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Supplementary Table B:  Detailed characteristics of studies 
Study Age, years (SD) Male Diabetes Prior MI NYHA Class Mean ejection fraction (SD) 
Oral 
anticoagulant ACEi/ARB Beta-blocker Digoxin 
Mean CHADS2 
score (SD) 
Badheka, 
2011 
rEF 68 (9) 
pEF 71 (8) 
rEF 74% 
pEF 49% 
rEF 29% 
pEF 28% 
rEF 40% 
pEF 21% 
Class >1: rEF 38% 
pEF 24% n/s 
rEF 90% 
pEF 89% 
rEF 77% 
pEF 51% 
rEF 37% 
pEF 44% 
rEF 76% 
pEF 64% 
rEF 2.5 (1.1) 
pEF 2.8 (1.1) 
Banerjee, 
2012 
rEF 71 (12) 
pEF 75 (13) 
rEF 77% 
pEF 50% 
rEF 24% 
pEF 26% 
rEF 50% 
pEF 31% n/s 
rEF 33% (9) 
pEF 60% (7) 
rEF 60% 
pEF 61% 
rEF 57% 
pEF 38% 
rEF 50% 
pEF 50% 
rEF 31% 
pEF 27% 
rEF 2.2 (1.0) 
pEF 2.6 (1.1) 
Eapen, 
2013 a 
rEF 79 (7) 
pEF 81 (7) 
rEF 61% 
pEF 37% 
rEF 36% 
pEF 35% 
rEF  39% 
pEF 23% n/s n/s 
rEF 49% 
pEF 47% 
rEF 64% 
pEF 54% 
rEF 62% 
pEF 55% n/s 
rEF 3.1 (1.2) 
pEF 3.3 (1.1) 
Fung, 
2007 
rEF 63 (7) 
pEF 74 (9) 
rEF 63% 
pEF 21% 
rEF 20% 
pEF 21% n/s 
Mean: rEF 2.76 (0.44) 
pEF 2.61 (0.51) 
rEF 29% (6) 
pEF 63% (9) n/s 
rEF 80% 
pEF 14% 
rEF 70% 
pEF 21% 
rEF 77% 
pEF 71% n/s 
Kotecha,  
2014 b 
rEF 67 (10) 
pEF 77 (5) 
rEF 82% 
pEF 47% 
rEF 23% 
pEF 23% 
rEF 40% 
pEF 25% 
rEF II 23%, III 65%, IV 8% 
pEF II 56%, III 38%, IV 4%  
rEF 27% (7) 
pEF 54% (8) 
rEF 59% 
pEF 36% 
rEF 95% 
pEF 89% randomized 
rEF 84% 
pEF 75% 
rEF 2.0 (1.0) 
pEF 2.6 (0.8) 
Linssen, 
2011 
rEF 71 (10) 
pEF 75 (9) 
rEF 70% 
pEF 57% 
rEF 25% 
pEF 26% 
rEF 40% 
pEF 22% 
rEF II 47%, III 50%, IV 3% 
pEF II 53%, III 42%, IV 5% 
rEF 26% (8) 
pEF 51% (9) 
rEF 93% 
pEF 86% 
rEF 88% 
pEF 78% 
rEF 69% 
pEF 55% 
rEF 59% 
pEF 50% n/s 
McManus, 
2013 c 78 (10) 52% 24% 11% n/s n/s 50% 56% 66% 30% n/s 
McMurray, 
2013 d 
rEF 68 (14) 
pEF 69 (14) 
rEF 79% 
pEF 58% 
rEF 27% 
pEF 25% 
rEF 28% 
pEF 18% 
rEF II 50%, III 22%, IV 1% 
pEF II 62%, III 21%, IV 1% 
rEF 35% (9) 
pEF 56% (12) 
rEF 61% 
pEF 51% 
rEF 81% 
pEF 77% 
rEF 75% 
pEF 69% 
rEF 47% 
pEF 39% 
rEF 2.2 (1.2) 
pEF 2.7 (1.1) 
Olsson, 
2006 
rEF 68 (10) 
pEF 71 (10) 
rEF 78% 
pEF 58% 
rEF 27% 
pEF 23% 
rEF 44% 
pEF 24% 
rEF II 29%, III 66%, IV 6% 
pEF II 56%, III 41% IV 3% 
rEF 29% (8) 
pEF 55% (9) 
rEF 77% 
pEF 73% 
ARB 
randomized 
rEF 50% 
pEF 45% 
rEF 80% 
pEF 66% n/s 
Pai, 
2007 c,e 72 (10) 97% n/s n/s n/s 47% (17) n/s n/s n/s n/s n/s 
Parkash, 
2005 a 
rEF 72 (13) 
pEF 76 (12) 
rEF 65% 
pEF 38% 
rEF 30% 
pEF 26% 
rEF 43% 
pEF 20% n/s 
rEF 33% (9) 
pEF 58% (7) 
rEF 77% 
pEF 78% 
rEF 70% 
pEF 43% 
rEF 58% 
pEF 59% 
rEF 58% 
pEF 46% n/s 
Pedersen, 
2005 b,c 75 62% 15% 27% n/s 33% n/s n/s n/s n/s n/s 
Shamagian, 
2006 
rEF 68 (11) 
pEF 72 (9) 
rEF 71% 
pEF 46% 
rEF 21% 
pEF 20% 
rEF 39% 
pEF 23% 
Class III/IV: rEF 77% 
pEF 74% n/s 
rEF 53% 
pEF 59% 
rEF 68% 
pEF 49% 
rEF 25% 
pEF 17% 
rEF 66% 
pEF 46% n/a 
SD, standard deviation; ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; rEF, reduced ejection fraction; pEF, preserved ejection fraction; n/s, not 
specified.  a Medication rates are those at time of discharge.  b Includes patients with AF and atrial flutter.  c rEF and pEF groups combined.  d rEF group includes asymptomatic patients; 
values are median (interquartile range).  e Symptom status unknown; quoted figures are for the whole AF population.   
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Supplementary Table C:  Adjusted comparative hazard ratios for all-cause mortality 
 
Study Ejection fraction cut-off 
Adjusted hazard ratio for all-cause mortality: AF-HFrEF versus AF-HFpEF 
Point estimate 95% CI Adjustment variables 
Badheka, 2011 ≥ 50% 1.61 1.18-2.17 
Age, gender, rhythm at randomization,  duration of AF, diabetes, 
hypertension, CAD, stroke, mitral regurgitation, smoking, NYHA class, 
ACEi, beta-blockers, CCB, digoxin, randomization arm 
Kotecha, 2014 ≥ 45% 1.33 0.83-2.12 
Age, gender, diabetes, previous MI, prior coronary revascularization, 
hypertension, heart rate, ACEi/ARB, digoxin, diuretic therapy, oral 
anticoagulation, randomization arm (study stratified) 
Parkash, 2005 >50% 1.09 0.80-1.48 
Age, gender, renal insufficiency, diabetes, hypertension, CAD, COPD,  
stroke, history of cancer, comorbid illnesses at the time of 
hospitalization including acute MI, infection, respiratory failure or 
pulmonary embolism, smoking, serum sodium, heart rate, ACEi, ARB, 
beta-blockers, aspirin, warfarin, digoxin, antiarrhythmic drugs, statins at 
discharge 
CAD, coronary artery disease; CCB, calcium channel blocker; COPD, chronic obstructive pulmonary disease. 
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Figure Legends 
 
Figure 1:  Study selection diagram 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram. 
 
Figure 2:  Meta-analysis of all-cause mortality 
Meta-analysis for the primary outcome, with the diamond and dotted line representing the 
pooled difference using a random-effects model.  I2 is the percentage of total variation across 
studies due to heterogeneity (p for heterogeneity=0.002). 
 
Figure 3:  Assessment of publication bias for all-cause mortality 
Funnel plot diagram for primary outcome demonstrating relative symmetry with no observable 
small-study effects (Begg’s p=0.47, Egger’s p=0.73). 
 
Figure 4:  Meta-analysis of incident stroke and heart failure-related hospitalization 
Random-effects model meta-analysis.  Incident stroke heterogeneity p=0.40.  Heart failure 
hospitalization heterogeneity p<0.001.   
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Supplementary Figure A:  Meta-analysis according to study design 
Fixed-effects model meta-analysis.  Interaction for study design p=0.02.  Post-hoc randomized 
controlled trial (RCT) group heterogeneity p=0.103.  Cohort study group heterogeneity p=0.111.  
Overall heterogeneity p=0.002. 
 
Supplementary Figure B:  Meta-analysis according to anticoagulation use 
Random-effects model meta-analysis.  Rate of anticoagulation interaction p=0.83.  >70% group 
heterogeneity p=0.002.  ≤70% group heterogeneity p=0.019.  Overall heterogeneity p=0.002.   
 
Supplementary Figure C:  Meta-analysis according to HFpEF cut-off 
Random-effects model meta-analysis.  HFpEF definition interaction p=0.17.  Left-ventricular 
ejection fraction (LVEF) ≥50% group heterogeneity p=0.10.  <50% definition group 
heterogeneity p=0.008.  Overall heterogeneity p=0.002. 
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